Azitra (AZTR) Receivables - Other (2022 - 2023)
Azitra (AZTR) reported Receivables - Other of $90000.0 for Q4 2023, down 48.57% on a YoY basis from $175000.0 in Q4 2022, and down 79.55% quarter-over-quarter from $440000.0 in Q2 2023.
Azitra (AZTR) Receivables - Other (2022 - 2023) Analysis & Trends
Azitra has reported Receivables - Other for 2 years, with the latest figure at $90000.0 in Q4 2023.
- For the quarter ending Q4 2023, Receivables - Other fell 48.57% year-over-year to $90000.0; the trailing twelve-month figure through Dec 2023 stood at $90000.0 (down 48.57% YoY), and the FY2023 full-year result was $90000.0, down 48.57% from the prior year.
- Receivables - Other for Q4 2023 stood at $90000.0, down from $440000.0 in the prior quarter.
- The five-year high for Receivables - Other was $440000.0 in Q2 2023, with the low at $90000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 90,000.00 |
| Dec 31, 2023 | 90,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Dec 31, 2022 | 175,000.00 |
| Dec 31, 2022 | 175,000.00 |